post a free press release
post a free press release post a free press release post a free press release post a free press release post a free press release post a free press release
post a free press release

Reimbursement of retinal implant for a limited number of patients

French health authority HAS approves Forfait Innovation application by Retina Implant AG

(Reutlingen, Germany/Saint-Denis, France) - French health authority HAS (Haute Autorite de Sante) has just approved the Forfait Innovation application by Retina Implant AG (https://www.retina-implant.de/en/) to assess the benefits of its RETINA IMPLANT Alpha AMS subretinal implant. The procedure evaluates innovative technologies in the healthcare sector to quickly make them available to patients. As part of the Forfait Innovation process, over a two-year period the costs will be covered for the implant and treatment of a limited number of patients who perceive little or no light. Retina Implant AG fund the costs for the accompanying study, which is examining the impact of the implant on participants` daily lives (Impact on daily life of patients using the subretinal implant RETINA IMPLANT Alpha AMS).

Following the successful conclusion of the study, the implant will be added to the list of approved services of health insurance companies in France. As a result of the reimbursement, an innovative technology can be made available to patients with the hereditary retinal disease retinitis pigmentosa (RP), which leads to total blindness in the final stage. Although RP is a rare disease, some 130,000 people suffer from it in Europe alone. The subretinal implant is virtually invisible except for a small transponder fixed behind the ear. The implant can partially restore the sight of blind people suffering from RP. This means a large proportion of patients can make out light sources with the RETINA IMPLANT Alpha AMS and thus find their way around a room, for example.

"For some time now, work has been in progress to focus attention on the practical benefits for visually impaired people in their everyday lives, alongside standard sight measurements. We`re delighted this study is taking particular account of this aspect," explains Jürgen Klein, Sales and Marketing Director at Retina Implant AG. "France is therefore taking a leading role in Europe in evaluating subretinal implants." The study will be performed in close cooperation between the university hospital CHU Montpellier for screening and patient follow-up and the implantation centre Clinique St Jean in Montpellier for the surgery, with further centres planned.

Pressekontakt Zeeb Kommunikation GmbH Anja Pätzold Hohenheimer Straße 58a 70184 Stuttgart 0711-60 70 719 info@zeeb.info http://www.zeeb-kommunikation.de

Retina Implant AG, Forfait Innovation, HAS, Alpha AMS, subretinal implant, Reimbursement

by: Retina Implant AG



Previous press releases
Kedai Mimpi Presents The Ultimate Sports Prediction Web Platform
Reduce Downtime With This New York Plane Repair Sp
Understanding Diabetes and Member Health
Buy Aachi Masala Online
Fantasy and folklore for October half term at Beaulieu
ARTS demonstrates its technical expertise at SpaceTech Expo Europe 2017
New Website AirportParkingHunter com Makes Airport Parking Easier To Find
Brief description about java
Mageworx Announced 2 Extensions for Magento 2 Landing Pages Popup Widget
What to Expect From Texas Holdem Rules
Hospital Manamegent Software
Asahi Kasei launches RandD Center in Germany
HOW TO GET RID OF CREDIT CARD DEBT
HOW TO GET RID OF CREDIT CARD DEBT
HOW TO GET RID OF CREDIT CARD DEBT
Investing in Proper Customer Support Chat
HOW TO GET RID OF CREDIT CARD DEBT
HOW TO GET RID OF CREDIT CARD DEBT
HOW TO GET RID OF CREDIT CARD DEBT
post a free press release
post a free press release